RxDoctor Payments Data

Bruce Houston, DO

Family Medicine · Albany, GANPI 1285629907

Payments from drug & device makers

$19,122in general payments, 2019–2025

Across 1,147 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • GSK$1K
  • Lilly USA, LLC$1K
  • AbbVie$982
  • Pfizer$941
  • plus $11K from 47 others

What the payments were for

  • Food & beverage$19,057100%
  • Education$650%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,122 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$1,428,036
Medicare patients
261
Services billed
8,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide273$329,103
MounjaroTirzepatide132$188,032
FarxigaDapagliflozin Propanediol182$171,750
JardianceEmpagliflozin135$126,867
XareltoRivaroxaban84$74,462
EliquisApixaban65$65,912
JanuviaSitagliptin Phosphate75$61,320
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$50,395
KerendiaFinerenone48$39,475
LinzessLinaclotide24$28,173
MyrbetriqMirabegron27$22,761
TrulicityDulaglutide21$22,041
TradjentaLinagliptin18$14,925
VascepaIcosapent Ethyl12$9,096
Atorvastatin Calcium871$8,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,494$329,103273 claims
Lilly USA, LLCMounjaro, Trulicity$1,144$210,073153 claims
AstraZenecaFarxiga$1,574$171,750182 claims
Boehringer IngelheimJardiance, Tradjenta$694$141,792153 claims
Johnson & JohnsonXarelto$767$74,46284 claims
PfizerEliquis$941$65,91265 claims
MerckJanuvia$575$61,32075 claims
GSKTrelegy Ellipta, Shingrix$1,382$53,23175 claims
BayerKerendia$931$39,47548 claims
AbbVieLinzess$982$28,17324 claims
Astellas Pharma US IncMyrbetriq$744$22,76127 claims
Esperion Therapeutics, Inc.Nexlizet$205$7,55713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →